What is Biogen's felzartamab (igan) — intangible assets:?

Biogen (BIIB) reported felzartamab (igan) — intangible assets: of $920.00M in Q2 2024.

What does felzartamab (igan) — intangible assets: mean?

The recorded book value of intellectual property and development rights for the Felzartamab drug program targeting IgAN.

Discontinued — last reported Q2 '24

Products & Services · Intangible assets:

Felzartamab (IgAN) — Intangible assets:

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ2 2024

Last reportedQ2 2024

Rolls up toIntangibles (Net)

How to read this metric

An increase typically reflects additional capital investment or acquisitions related to the asset, while a decrease may indicate amortization or impairment charges suggesting reduced commercial expectations.

Detailed definition

This metric represents the capitalized value of intangible assets specifically associated with the development and comme...

Peer comparison

Comparable to capitalized in-process research and development (IPR&D) or acquired intangible assets reported by other biopharmaceutical firms for specific late-stage clinical pipeline assets.

Metric ID: biib_segment_felzartamab_igan_intangible_assets

Historical Data

1 periods

	Q2 '24
Value	$920.00M

Similar Metrics at Other Companies

InsmedINSM View metric

ViatrisVTRS View metric

InsmedINSM View metric

Vertex PharmaceuticalsVRTX View metric

Frequently Asked Questions

What is Biogen's felzartamab (igan) — intangible assets:?: Biogen (BIIB) reported felzartamab (igan) — intangible assets: of $920.00M in Q2 2024.
What does felzartamab (igan) — intangible assets: mean?: The recorded book value of intellectual property and development rights for the Felzartamab drug program targeting IgAN.